Insulet Corporation PODD

Insulet Corporation se dedica principalmente al desarrollo, fabricación y venta de su sistema patentado Omnipod, un sistema de administración continua de insulina para personas con diabetes dependiente de la insulina. El sistema Omnipod incluye el Sistema de Gestión de Insulina Omnipod (Omnipod), el Sistema de Gestión de Insulina Omnipod DASH (Omnipod DASH) y su plataforma móvil digital Omnipod. El sistema Omnipod cuenta con dos dispositivos: un dispositivo Omnipod desechable, sin tubo, pequeño, ligero y autoadhesivo (Pod) y un Administrador Personal de Diabetes (PDM). Los usuarios deben llenar el Pod con insulina y llevarlo directamente en el cuerpo. Se puede llevar en múltiples ubicaciones, incluyendo el abdomen, cadera, parte trasera del brazo superior, muslo superior o parte baja de la espalda. El Pod administra dosis precisas y personalizadas de insulina en el cuerpo a través de un pequeño tubo flexible, cánula. El PDM es un dispositivo inalámbrico portátil que programa el Pod con las instrucciones personalizadas de administración de insulina del usuario y monitorea de forma inalámbrica la operación del Pod.

• Zacks Investment Research 8 sept

  Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

  Insulet's Q2 Omnipod revenues grew 23.8% at constant currency with expanding global adoption, particularly for its Omnipod 5 automated insulin delivery system. The company raised 2026 international guidance and is progressing on next-generation products including Omnipod 6. However, intense competition, macroeconomic pressures, and supply chain risks could limit future margin expansion and profitability.

  

• GlobeNewswire Inc. 29 ago

  ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Blaize Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - BZAI

  Rosen Law Firm has filed securities class action lawsuits against Blaize Holdings, Inc. and Hyliion Holdings Corp., alleging false statements and improper revenue recognition. Investors who purchased securities during specified periods are encouraged to join the class action before the October 5, 2026 deadline for lead plaintiff status. The firm is also handling a case against Insulet Corporation with an August 31 deadline.

  

• GlobeNewswire Inc. 29 ago

  ROSEN, A NATIONALLY RECOGNIZED LAW FIRM, Encourages Hyliion Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HYLN

  Rosen Law Firm has filed class action lawsuits against Hyliion Holdings Corp. (HYLN) for alleged false statements regarding a business deal with a recently formed entity lacking actual operations, and potential insider trading by executives. A separate class action has been filed against Insulet Corporation (PODD) with an August 31, 2026 deadline for lead plaintiff motions. Both lawsuits allege material misstatements that caused investor losses.

  

• GlobeNewswire Inc. 29 ago

  PODD 截止日期為星期一：全美審訊法律顧問 ROSEN 鼓勵損失超過 10 萬美元的 Insulet Corporation 投資者在對 PODD 提出證券集體訴訟的重要截止日期 8 月 31 日前聘請律師

  Rosen Law Firm reminds investors in Insulet Corporation (PODD) and Primoris Services Corporation (PRIM) of important class action lawsuit deadlines. Investors who purchased securities during specified periods and suffered losses exceeding $100,000 are encouraged to secure legal counsel before the August 31, 2026 deadline to potentially recover damages through contingency fee arrangements.

  

• GlobeNewswire Inc. 29 ago

  PODD DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Insulet Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important August 31 Deadline in Securities Class Action – PODD

  Rosen Law Firm reminds investors of Insulet Corporation who purchased securities between February 21, 2025 and May 26, 2026 of the August 31, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that Insulet made false statements regarding defective manufacturing controls and procedures that created safety risks, resulting in investor damages.